4Q preview: AbbVie, AZ, Gilead, GSK, Lilly, Merck, Novo Nordisk and Sanofi
This article was originally published in Scrip
The full year reporting season is in full swing, with Bristol-Myers Squibb, Pfizer, Amgen, Novartis and Roche, among others, having reported a mixed set of numbers this week.
You may also be interested in...
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.